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Abstract
Objectives—To determine whether defining diurnal periods by self-report, fixed-time or 
actigraphy produce different estimates of nighttime and daytime ambulatory blood pressure 
(ABP).
Methods—Over a median of 28 days, 330 participants completed two 24-hour ABP and 
actigraphy monitoring periods with sleep diaries. Fixed nighttime and daytime periods were 
defined as 00:00–06:00 and 10:00–20:00, respectively. Using the first ABP period, within-
individual differences for mean nighttime and daytime ABP and Kappa statistics for nighttime and 
daytime hypertension (systolic/diastolic ABP ≥120/70 mmHg and ≥135/85 mmHg, respectively) 
were estimated comparing self-report, fixed-time or actigraphy for defining diurnal periods. 
Reproducibility of ABP was also estimated.
Results—Within-individual mean differences in nighttime systolic ABP were small, suggesting 
little bias, when comparing the three approaches used to define diurnal periods. The distribution of 
differences, represented by 95% confidence intervals (CI), in nighttime systolic and diastolic ABP 
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and daytime systolic and diastolic ABP was narrowest for self-report versus actigraphy. For 
example, mean differences (95% CI) in nighttime systolic ABP for self-report versus fixed-time 
was −0.53 (−6.61,+5.56) mmHg, self-report versus actigraphy was 0.91 (−3.61,+5.43) mmHg and 
fixed-time versus actigraphy was 1.43 (−5.59,+8.46) mmHg. Agreement for nighttime and 
daytime hypertension was highest for self-report versus actigraphy: Kappa statistic (95% CI)=0.91 
(0.86,0.96) and 1.00 (0.98,1.00), respectively. The reproducibility of mean ABP and hypertension 
categories was similar using each approach.
Conclusion—Given the high agreement with actigraphy, these data support using self-report to 
define diurnal periods on ABP monitoring. Further, the use of fixed-time periods may be a 
reasonable alternative approach.
Keywords
ambulatory blood pressure; sleep; diurnal periods; daytime; nighttime; clinic blood pressure; blood 
pressure
Introduction
Ambulatory blood pressure monitoring (ABPM) measures out-of-clinic blood pressure (BP), 
typically over 24 hours. Using ABPM, several diurnal ambulatory BP (ABP) parameters can 
be derived including mean nighttime and daytime ABP (i.e., the mean of ABP readings 
during the nighttime and daytime periods, respectively) and BP non-dipping status (i.e., 
ABP ratio >0.90 between the nighttime and daytime periods).[1] Higher mean nighttime 
ABP, daytime ABP and BP non-dipping status have been associated with increased risk for 
target-organ damage, cardiovascular disease (CVD) and all-cause mortality, independent of 
clinic blood pressure (CBP).[1–3]
Nighttime and daytime periods on ABPM can be defined using several approaches: self-
reported, fixed-time, or less commonly, actigraphy.[4–6]Few hypertension guidelines, 
position papers or scientific statements that recommend ABPM describe how best to assess 
the nighttime and daytime periods in clinical practice.[7–15] The guidelines, position papers 
and scientific statements that provide recommendations endorse self-report and fixed-time 
period approaches but there are limited empirical evidence to support their use.[1, 16–18] 
Whereas self-report is subject to recall bias, fixed-time periods may have limited ecological 
validity since the time when people go to sleep and awaken may differ between individuals 
and also within the same individual on separate days.[1, 6] Also, fixed-time periods may 
omit the typical sleep-awake transition periods[6, 19] and important BP fluctuations during 
the sleep-awake transition periods, including the morning BP surge which has been 
associated with an increased risk for CVD events in some studies.[1] Actigraphy requires a 
device to be worn for 24 hours and it may be difficult to employ in clinical practice.
Mean nighttime and daytime ABP and the degree of nighttime BP dipping may differ 
depending on which approach is used to define the daytime and nighttime periods. The 
current study evaluated (1) whether utilizing self-reported, fixed-time and actigraphy 
approaches to define the nighttime and daytime periods produce different estimates of 
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diurnal ABP parameters, and (2) whether the reproducibility of diurnal ABP parameters 
differs by the approach used.
Methods
Study population
The Improving the Detection of Hypertension (IDH) study is a community-based study that 
enrolled adult participants primarily from the communities comprising upper Manhattan in 
New York City. Participants were excluded if they had any of the following: screening 
systolic CBP ≥160 mmHg or diastolic CBP ≥105 mmHg; evidence of secondary 
hypertension; were taking antihypertensive or other medications known to affect BP (i.e. 
steroids, tricyclic antidepressants, etc.); history of overt CVD, chronic kidney disease, liver 
disease, adrenal disease, thyroid disease, rheumatologic disease, hematologic disease, and 
cancer or dementia; were pregnant; or had a history of organ transplantation.
Between March 2011 and October 2013, 375 participants were enrolled in the IDH study. 
Participants who did not have complete data on CBP, ≥80% of the ABPM readings during 
the two planned ABPM periods, and complete sleep and awake times derived from self-
report and actigraphy were excluded. After these exclusions, the current analysis included 
330 participants. The Institutional Review Board at Columbia University approved the 
current study and this statistical analysis was approved by the Institutional Review Board at 
the Univesity of Alabama at Birmingham. All participants provided written informed 
consent.
Overview of study procedures
Sociodemographic and CVD risk factor information were collected using self-administered 
questionnaires and through two clinical exam visits (i.e., anthropometric measurements, bio-
specimen assays). The median (25th–75th percentile) time between the two visits was 28 
(23–36) days. Following each visit, participants began 24-hour ABPM and actigraphy 
(ABPM periods 1 and 2).
Sociodemographic and CVD risk factors
Highest level of education completed was categorized as less than versus at least a high 
school/general education diploma. Annual household income was categorized as less than or 
greater than or equal to $30,000 USD. Participants were categorized as being current 
smokers or non-smokers based on self-report. Alcohol use was defined as non-drinker (no 
weekly alcohol consumption), moderate drinker (1–14 and 1–7 alcoholic beverages per 
week for men and women, respectively) or heavy drinker (>14 and >7 alcoholic beverages 
per week for men and women, respectively). Body mass index (BMI) was calculated as 
weight in kilograms (kg) divided by height in meters squared. BMI was categorized as 
normal (≥18 and <25 kg/m2), overweight (≥25 and <30 kg/m2) and obese (≥30 kg/m2). 
Diabetes was defined as a self-reported prior physician diagnosis. An enzymatic 
colorimetric assay was used for determining fasting total cholesterol, triglycerides, and high-
density lipoprotein (HDL) cholesterol concentrations. The Friedewald equation was used to 
calculate low-density lipoprotein (LDL) cholesterol.[20] Fasting glucose and hemoglobin 
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A1c were also measured. High-sensitivity C-reactive protein (hs-CRP) was measured by 
particle-enhanced immunonephelometry. Urinary albumin and creatinine were measured, 
and the urinary albumin-to-creatinine ratio was calculated.
CBP measurement
At each of the two clinic visits, BP was measured three times by trained technicians 
following a standardized protocol using a mercury sphygmomanometer (Baum, Copiague, 
NY), appropriately sized BP-cuff and stethoscope. Prior to the first CBP measurement, 
participants sat for five minutes with both feet on the floor. There was at least one minute 
between BP measurements. Mean CBP at each visit was calculated by averaging the three 
systolic and diastolic measurements, separately. Clinic hypertension was defined as mean 
systolic CBP ≥140 mmHg or diastolic CBP ≥90 mmHg.
ABPM
ABPM and actigraphy were simultaneously performed over a 24 hour period. Each 
participant was fitted with an appropriate-sized ABPM arm cuff (Spacelabs Model 90207, 
Snoqualmie, WA). ABP was recorded every 30 minutes. The editing criteria used to exclude 
readings were systolic ABP <70mmHg or >260mmHg and/or diastolic ABP <40mmHg or 
>150mmHg. A valid 24-hour ABPM recording was defined as having ≥80% of the total 
planned ABPM readings. Mean daytime and nighttime systolic and diastolic ABP and the 
nighttime BP dipping were calculated using each approach for defining the nighttime and 
daytime periods (described below).
Nighttime hypertension was defined as mean nighttime systolic ABP ≥120 mmHg or mean 
nighttime diastolic ABP ≥70 mmHg.[1, 21] Daytime hypertension was defined as mean 
daytime systolic ABP ≥135 mmHg or mean daytime diastolic ABP ≥85 mmHg.[1, 22] 
Nighttime BP dipping was calculated as the ratio of mean nighttime to mean daytime 
systolic ABP. Non-dipping status was defined as nighttime BP dipping >0.90.[1] The 
magnitude of dipping status was also categorized into four groups based on nighttime BP 
dipping: extreme dipping (≤0.80), normal dipping (>0.80 to ≤0.90), non-dipping (>0.90 to 
≤1.00) and reverse dipping (>1.00).[1]
Nighttime and daytime periods
Nighttime and daytime periods were determined using three approaches: self-report using a 
sleep diary, fixed-time periods, and wrist actigraphy. Upon completion of each 24-hour 
ABPM period, participants completed a sleep diary of the times they went to sleep and 
awoke during the 24-hour ABPM period. Fixed-time periods were defined by the 
International Database of ABP in relation to Cardiovascular Outcome (IDACO) criteria for 
Europeans (nighttime: 00:00 to 06:00 [6 hours], daytime: 10:00 to 20:00 [10 hours]).[6, 19] 
Additionally, sleep and awake periods were estimated from a wrist actigraphy device 
(ActiWatch, Phillips Respironics, Murrayville, PA) worn on the non-dominant wrist using 
ActiWatch processing software.[23]
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Statistical analysis
Characteristics were calculated as percentages or means and standard deviations. Using data 
collected during ABPM period 1, the mean (95% CI) and absolute value (95% CI) of the 
total nighttime period (in minutes) and pairwise within-individual differences, self-reported 
versus fixed-time, self-reported versus actigraphy, and fixed-time versus actigraphy, were 
plotted. The distribution of the clock time for the start of the nighttime and daytime periods, 
separately, were also plotted. Pairwise systematic differences of nighttime systolic and 
diastolic ABP were assessed using Bland-Altman plots. On a Bland-Altman plot, the 
average of the differences in measurements between each method corresponds to the 
average bias. The 95% CI provides a measure of the spread of the within-individual 
differences. Pearson linear correlation coefficients were estimated for ABP comparing each 
pairwise approach for defining the diurnal periods. The prevalence of nighttime 
hypertension, daytime hypertension, non-dipping status, and dipping status categories was 
calculated for each approach. Overall percent agreement and the Kappa statistic were 
calculated for pairwise comparisons for defining diurnal periods. The Kappa statistic 
provides an estimate of concordance after accounting for the expected agreement by chance 
alone.[24] Agreement was classified into the following levels: poor (−1.00 to 0.00), slight 
(>0.00 to 0.20), fair (>0.20 to 0.40), moderate (>0.40 to 0.60), substantial (>0.60 to 0.80), 
and almost perfect (>0.80 to 1.00).[24] Additionally, estimates of the prevalence and 
agreement were calculated using a more stringent definition requiring the presence of 
nighttime hypertension, daytime hypertension, non-dipping status and magnitude of dipping 
status categories during both ABPM periods 1 and 2.
Next, the reproducibility of the duration of the nighttime period, mean nighttime and 
daytime systolic and diastolic BP, and hypertension categories between ABPM periods 1 
and 2 were estimated for each approach to defining the diurnal period using the intra-class 
correlation coefficient (95% CI) for continuous measures and the Kappa statistic (95% CI) 
for categorical measures. Paired t-tests and McNemar’s Chi Square Test of paired 
proportions were used to evaluate differences in mean values and the prevalence of 
hypertension categories between ABPM periods 1 and 2 for each approach (self-report, 
fixed and actigraphy). Analyses were conducted using Stata/IC 13.1 (Stata Corporation, 
College Station, Texas).
Results
Participant characteristics
Table 1 shows the characteristics of the study population. Participants’ mean age was 40.5 
(SD 13.0) years. Also, 41.8% of the population was male and 20.6% and 64.5% of 
participants were black and Hispanic, respectively.
Duration of the diurnal periods
The median (25th–75th percentiles) total duration of the nighttime period for participants 
using the self-reported and actigraphy approaches was 450 (395–510) minutes and 412 
(360–468) minutes, respectively (Figure 1, Panel A). All participants had 360 minutes of 
sleep using fixed-time. The median (25th–75th percentiles) absolute difference of the 
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nighttime period duration for self-report versus fixed-time approach was 93 (50–150) 
minutes, self-report versus actigraphy approach was 36 (16–71) minutes, and fixed-time 
versus actigraphy approach was 67 (30–122) minutes (Figure 1, Panel B). The median total 
duration of the daytime period (25th–75th percentiles) using the self-report, fixed-time, and 
actigraphy approaches, and the median (25th–75th percentiles) absolute difference between 
the three approaches are shown in Supplemental Figure 1 (Panels A and B).
Figure 2 shows the cumulative distribution of clock times for the start of the nighttime 
period assessed by self-report (Panel A) and actigraphy (Panel B). The cumulative 
distribution of clock times for the start of the daytime period are shown in Supplemental 
Figure 2 (Panels A and B). The percentage of participants who had a clock time for sleep 
onset after 00:00 AM was 43.3% by self-report and 55.2% by actigraphy. The percentage of 
participants who had a clock time for awakening after 06:00 AM was 87.3% and 78.5% for 
self-reported and actigraphy approaches, respectively, and after 10:00 AM was 5.5% and 
7.3%, respectively.
Nighttime ABP
During ABPM period 1, the mean (95% CI) nighttime systolic ABP was 110 (109–111) 
mmHg for self-report, 111 (109–112) mmHg for fixed-time and 109 (108–111) mmHg for 
the actigraphy approach. The mean (95% CI) nighttime diastolic ABP was 65 (64–65) 
mmHg for self-report, 65 (64–66) mmHg for fixed-time and 64 (63–65) mmHg for the 
actigraphy approach.
For nighttime systolic ABP, the Pearson linear correlation coefficients (95% CI) comparing 
self-report versus fixed-time, self-report versus actigraphy, and fixed-time versus actigraphy 
were 0.97 (0.96–0.97), 0.98 (0.98–0.98) and 0.95 (0.94–0.96) and for nighttime diastolic 
ABP were 0.96 (0.95–0.97), 0.97 (0.96–0.97) and 0.93 (0.92–0.95), respectively.
Figure 3 shows the systematic differences in nighttime systolic (Panel A) and diastolic ABP 
(Panel B) between the three approaches for defining diurnal periods. The mean difference 
(95% CI) in systolic ABP was −0.53 (−6.61 to 5.56) mmHg for self-reported versus fixed-
time, 0.91 (−3.61 to 5.43) mmHg for self-reported versus actigraphy and 1.43 (−5.59 to 
8.46) mmHg for fixed-time versus actigraphy. The mean differences (95% CI) in diastolic 
ABP comparing self-reported versus fixed-time, self-reported versus actigraphy and fixed-
time versus actigrpahy was −0.44 (−5.45 to 4.57), 0.74 (−3.53 to 5.02) and 1.19 (−5.00 to 
7.34) mmHg, respectively.
Daytime ABP
During ABPM period 1, the mean (95% CI) daytime systolic ABP was 124 (123–126) 
mmHg for self-report, 125 (124–126) mmHg for fixed-time and 124 (123–125) mmHg for 
the actigraphy approach. The mean (95% CI) daytime diastolic ABP was 78 (77–79) mmHg 
for self-report, 79 (78–79) mmHg for fixed-time and 78 (77–78) mmHg for the actigraphy 
approach. The Pearson linear correlation coefficients (95% CI) for daytime systolic ABP 
were 0.98 (0.97–0.98), 1.00 (0.99–1.00), and 0.97 (0.97–0.98) comparing self-report versus 
fixed-time, self-report versus actigraphy, and fixed-time versus actigraphy, respectively. The 
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Pearson linear correlation coefficients (95% CIs) was >0.95 for all pairwise comparisons of 
estimating daytime diastolic ABP. Supplemental Figure 3 shows the systematic differences 
in daytime systolic (Panel A) and diastolic (Panel B) ABP between the three approaches for 
defining diurnal periods.
Prevalence of hypertension categories at ABPM period 1
At ABPM period 1, clinic hypertension was present in 12.5% of participants. The 
prevalence and agreement of nighttime hypertension, daytime hypertension, non-dipping 
status, and magnitude of dipping status categories are shown in Table 2 for the self-report, 
fixed-time, and actigraphy-based approaches. The highest agreement for nighttime 
hypertension, daytime hypertension, non-dipping status, and magnitude of dipping status 
categories was between self-reported versus actigraphy (Table 2). The prevalence and 
agreement for nighttime hypertension, daytime hypertension, and non-dipping status, 
comparing each of the three approaches were similar when defining hypertension based on 
its presence during both ABPM periods 1 and 2 (Supplemental Table 1).
Reproducibility of ABP parameters between ABPM periods 1 and 2
The intra-class correlation coefficients (95% CI) for systolic CBP was 0.71 (0.66–0.76) and 
0.63 (0.56–0.69) for diastolic CBP across ABPM periods 1 and 2. The kappa statistic (95% 
CI) for clinic hypertension across the two ABPM periods was 0.47 (0.32–0.62). Using self-
report, fixed-time and actigraphy for defining the diurnal periods, the intra-class correlation 
coefficients were substantial to almost perfect for nighttime and daytime systolic ABP and 
nighttime and daytime diastolic ABP, and fair to moderate for nighttime BP dipping (Table 
3). The Kappa statistic for the agreement across ABPM periods 1 and 2 was moderate to 
substantial for daytime hypertension and substantial for nighttime hypertension, fair to 
moderate for non-dipping status and fair for magnitude of dipping status using each of the 
three approaches.
Discussion
Using self-reported, fixed-time or actigraphy approaches to define the nighttime and 
daytime periods on ABPM may lead to different estimates of ABP. There are scarce 
empirical data on diurnal ABP parameters and reproducibility of ABP parameters using the 
three approaches studied in the same population. In the current analysis, the systematic 
biases in nighttime and daytime systolic and diastolic ABP were small when diurnal periods 
were defined by self-report, fixed-time or actigraphy. Further, the prevalence of nighttime 
hypertension, daytime hypertension, and BP non-dipping status were similar regardless of 
the approach used to define diurnal periods. However, there were large individual-level 
differences in systolic and diastolic nighttime and daytime ABP between approaches as 
demonstrated by wide 95% CIs. The narrowest to widest 95% CIs for nighttime systolic and 
diastolic ABP were for the comparison between self-report versus actigraphy, followed by 
self-report versus fixed-time, and fixed-time versus actigraphy. Also, self-report versus 
actigraphy had consistently higher agreement for hypertension status compared with self-
report or actigraphy with fixed time periods. Finally, using the two ABPM periods 
conducted approximately 28 days apart, the reproducibility of mean ABP, nighttime BP 
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dipping, and nighttime and daytime hypertension was similar for the three approaches used 
to define diurnal periods.
Nighttime ABP and non-dipping BP status have been associated with increased risk for 
CVD outcomes and mortality, independent of mean daytime ABP.[25, 26] In a prior 
systematic review, each 10-mmHg higher nighttime ABP was associated with a higher 
incidence of CVD events and mortality.[25] Additionally, individuals with non-dipping 
status were more likely to have CVD events and die compared with their counterparts with 
nighttime BP dipping.[25] Of the 16 studies identified by the systematic review, the 
nighttime and daytime periods were defined using self-report diaries in 6 studies, and a 
fixed-time approach in 10 studies.[25] Although actigraphy has been used in prior ABPM 
studies, scarce data exist on the associations of nighttime ABP parameters with outcomes 
using this method to define the nighttime period.[27, 28] In the current study, the mean 
differences in nighttime and daytime ABP were small for all comparisons between 
approaches. Further, the prevalence of nighttime hypertension, daytime hypertension, and 
non-dipping status were similar regardless of the approach used to define the nighttime and 
daytime periods. Therefore, from a population-level, each of the three approaches (self-
report, fixed-time, actigraphy) are satisfactory in estimating nighttime and daytime ABP and 
nighttime and daytime hypertension, and no approach is likely to be superior to use when 
estimating the association between ABP and CVD events.
The 2013 European Society of Hypertension (ESH) position paper on ABPM recommended 
that the daytime and nighttime periods be defined using self-report, but stated fixed-time 
periods may also be used.[1] The use of validated measurement devices (e.g., actigraphy) to 
determine daytime and nighttime periods was not mentioned in the ESH position paper.[1] 
Using each of the three approaches for defining diurnal periods (self-report, fixed-time, 
actigraphy) has limitations. The internal validity of self-report is compromised by recall 
bias. Defining diurnal periods by self-report diaries requires adherence of the individual to 
accurately report sleep and wake times, whereas actigraphy requires the individual to wear 
the device for 24 hours simultaneously with the ABPM. Also, actigraphy may be difficult to 
employ in clinical practice due to its relatively high purchase cost and the required training 
needed to download and analyze the recorded data. Ecological validity is limited for fixed-
time periods since nighttime and daytime periods may differ inter-individually and also 
intra-individually across time.[1, 6] Also, fixed-time periods may omit important BP 
fluctuations (e.g., morning BP surge) during the sleep-awake transition period that is 
associated with CVD risk.[1]
In the current study, the self-report and actigraphy approaches had the closest individual-
level values in nighttime and daytime ABP and nighttime and daytime hypertension, 
whereas the fixed-time approach had less agreement with either self-report or actigraphy. In 
a prior retrospective study of 95 clinic patients, the within-individual estimates of nighttime 
BP were similar for the self-report versus fixed-time (01:00 to 07:00 [6 hours]) approaches.
[29] Comparing self-report, fixed-time and actigraphy was not possible since diurnal periods 
were not objectively assessed.[29] The contrasting results for self-report versus fixed-time 
between the current and prior study may be attributed to differences in the sample sizes and 
populations (i.e., population-based not taking antihypertensive medications and clinic-based 
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taking antihypertensive medications, respectively). Also, the prior study estimated the mean 
ABP by averaging the mean hourly ABP levels, not by using each BP measurement 
recorded during the diurnal period as in the current study. The results herein suggest it may 
be reasonable to primarily use self-report in clinical practice to define the nighttime and 
daytime periods due to its ease in implementation over actigraphy. If self-report is unreliable 
for a particular individual, a fixed-time approach may be appropriate with the caveat that 
estimates of ABP for this individual may differ from estimates obtained by self-report.
The reproducibility of ABP parameters is also important to consider when choosing a 
method in determining the daytime and nighttime periods.[30] Eissa analyzed ABP data 
among 62 participants aged 6 to 71 years old comparing sleep and awake periods defined by 
actigraphy and self-report.[30] There were no differences in sleep or awake ABP or in 
daytime and nighttime hypertension status across the sample for actigraphy versus self-
report. However, 32% and 23% of participants were reclassified as having a nighttime BP 
non-dipping or dipping pattern, respectively, when using the self-report rather than 
actigraphy approach.[30]. As scarce data exist on comparisons between all three approaches 
(fixed-time, self-report, actigraphy) to estimate ABP parameters, our study provides 
essential information to the published literature. The results of the current study indicate the 
reproducibility across time is similar across each of the three assessed approaches.
There are several strengths of the current study. The IDH Study is one of the largest studies 
of ABP in which data are available at two visits to compare self-report, fixed-time and 
actigraphy approaches for determining the diurnal periods for estimating ABP parameters. 
Also, ABPM and the self-report and actigraphy approaches used to estimate the nighttime 
period were conducted following a standardized protocol in all participants. There are also 
several possible limitations of the current study. The results may have limited 
generalizability since the study cohort was relatively young, few participants had clinic 
hypertension, diabetes, chronic kidney disease and no participants were taking 
antihypertensive medication. Additionally, the study participants were from a single, large 
urban community and may not represent populations living outside of a large city who may 
have different sleep patterns.
In conclusion, there are scarce empirical data comparing self-reported, fixed-time and 
actigraphy approaches for estimating ABP during the nighttime and daytime periods on 
ABPM. The results reported herein indicate that using these three approaches to define 
diurnal periods on ABPM provide similar population estimates of nighttime and daytime 
ABP and nighttime and daytime hypertension. For most individuals, the differences in 
nighttime and daytime ABP and nighttime and daytime hypertension were smallest when 
comparing self-report versus actigraphy. The current study provides evidence that self-
report, which is more easily implemented in clinical practice than actigraphy, can be used to 
define diurnal periods on ABPM. Further, the fixed-time approach may be a reasonable 
alternative when self-report data is not available.
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Figure 1. 
Box and whisker plots of the total time during the nighttime period (Panel A) and the 
absolute value of the within-individual differences in time during the nighttime period 
(Panel B) defined by self-reported, fixed-time* and actigraphy during ambulatory blood 
pressure monitoring period 1 (n = 330).
*Using the definition of the International Database of Ambulatory Blood Pressure in relation 
to Cardiovascular Outcome (IDACO) for Europeans (nighttime: 0000 to 0600).
The median value is represented by the solid line inside the shaded box.
The shaded region below the median value represents the values between the median and 
25th percentile.
The shaded region above the median value represents the values between the median and 
75th percentile.
The whiskers represent the minimum and maximum values.
The diamond (◆) represents the mean value.
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Figure 2. 
Cumulative distribution of the clock time for start of the nighttime period by self-report 
(Panel A) and actigraphy (Panel B) on ambulatory blood pressure monitoring period 1.
The earliest and latest sleep onset clock times were 12:00 and 04:20 for self-report (median: 
23:45) and 12:46 and 07:12 (median: 00:10) using actigraphy, respectively.
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Figure 3. 
Bland-Altman plots comparing the systematic differences of nighttime systolic (Panel A) 
and diastolic (Panel B) blood pressure defined by self-reported, fixed-time* and actigraphy-
derived times from ambulatory blood pressure monitoring period 1 (n = 330).
*Using the definition of the International Database of Ambulatory Blood Pressure in relation 
to Cardiovascular Outcome (IDACO) for Europeans (nighttime: 0000 to 0600).
SBP: systolic blood pressure.
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DBP: diastolic blood pressure.
CI: confidence interval.
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Table 1
Characteristics of participants in the Improving the Detection of Hypertension Study.
Number of participants (n = 330)
Age 40.5 ± 13.0
Race/ethnicity
 Black 20.6%
 Hispanic 64.5%
Male 41.8%
Education less than high school 11.8%
Annual income less than $30,000 USD 47.9%
Body mass index (kg/m2) 27.5 ± 5.0
 Normal (<25) 33.4%
 Overweight (≥25 and < 30) 42.7%
 Obese (≥30) 23.9%
Total cholesterol (mg/dL) 182.3 ± 38.0
Low-density-lipoprotein cholesterol (mg/dL) 109.8 ± 33.3
C-reactive protein (mg/L) 1.36 (0.55 – 3.25)
Family history of hypertension 11.8%
Diabetes 4.5%
Current cigarette smoking 8.8%
Alcohol consumption*
 None 43.3%
 Moderate 51.5%
 Heavy 5.2%
Table numbers are percentages or mean ± standard deviation, except C-reactive protein which is median (25th – 75th percentile).
ABPM: ambulatory blood pressure monitoring. USD: US dollars.
*Alcohol use defined as: non-drinker (no weekly alcohol consumption), moderate drinker (1–14 and 1–7 alcoholic beverages per week for men and 
women, respectively) or heavy (>14 and >7 alcoholic beverages per week for men and women, respectively).
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